Trials / Terminated
TerminatedNCT01251354
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
A Phase II, International, Multicenter, Open-label, Proof of Concept Study of BN83495 in Postmenopausal Women With Advanced, Metastatic or Recurrent Oestrogen Receptor (ER) Positive Endometrial Carcinoma Who Have Received One Line of Chemotherapy in the Adjuvant or Metastatic Setting.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BN83495 | 1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-06-01
- Completion
- 2011-07-01
- First posted
- 2010-12-01
- Last updated
- 2019-01-14
- Results posted
- 2015-09-02
Locations
9 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01251354. Inclusion in this directory is not an endorsement.